Week In Review: ZAI Lab To Develop BMS Liver Cancer Drug In China

ZAI Lab of Shanghai in-licensed China rights to a liver cancer drug candidate from Bristol-Myers Squibb. Brivanib is an oral kinase inhibitor that is in Phase III trials for oncology indications.